Effects of genetic liability to Alzheimers disease on circulating metabolites across the life course
暂无分享,去创建一个
Y. Ben-Shlomo | E. Anderson | C. Bull | M. L. Smith | R. Korologou-Linden | Y. Ben-Shlomo | J. Bell | H. Compton | Madeleine L. Smith | Joshua A Bell | Hannah Compton
[1] Laurent F. Thomas,et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease , 2021, Nature Genetics.
[2] R. Dobson,et al. Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer’s disease , 2021, Proceedings of the National Academy of Sciences.
[3] E. Ware,et al. Type 2 Diabetes and Cognitive Status in the Health and Retirement Study: A Mendelian Randomization Approach , 2021, Frontiers in Genetics.
[4] Ariel K. Frame,et al. Determining the role of lactate metabolism on age‐dependent memory decline and neurodegeneration in Drosophila melanogaster , 2020, Alzheimer's & Dementia.
[5] Weiqi Chen,et al. Glycemic traits and Alzheimer’s disease: a Mendelian randomization study , 2020, Aging.
[6] G. Bu,et al. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease , 2020, Molecular Neurodegeneration.
[7] Matthew S. Gentry,et al. APOE4 Lowers Energy Expenditure and Impairs Glucose Oxidation by Increasing Flux through Aerobic Glycolysis , 2020, bioRxiv.
[8] Jie Zan,et al. Untargeted lipidomics reveals progression of early Alzheimer’s disease in APP/PS1 transgenic mice , 2020, Scientific Reports.
[9] Valeriia Haberland,et al. The MRC IEU OpenGWAS data infrastructure , 2020, bioRxiv.
[10] J. Tolstrup,et al. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals , 2020, Epidemiology and Psychiatric Sciences.
[11] D. Michaelson,et al. Central and Peripheral Mechanisms in ApoE4-Driven Diabetic Pathology , 2020, International journal of molecular sciences.
[12] James R. Staley,et al. A robust and efficient method for Mendelian randomization with hundreds of genetic variants , 2020, Nature Communications.
[13] Matthew S. Gentry,et al. APOE alters glucose flux through central carbon pathways in astrocytes , 2020, Neurobiology of Disease.
[14] M. Delorenzi,et al. Systemic and central nervous system metabolic alterations in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.
[15] D. Bennett,et al. Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis , 2019, Neurobiology of Aging.
[16] N. Timpson,et al. Early Metabolic Features of Genetic Liability to Type 2 Diabetes: Cohort Study With Repeated Metabolomics Across Early Life , 2019, Diabetes Care.
[17] D. Hervás,et al. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. , 2019, Journal of proteomics.
[18] Tom R. Gaunt,et al. The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019 , 2019, Wellcome open research.
[19] G. Davey Smith,et al. Can Mendelian Randomization Shift into Reverse Gear? , 2019, Clinical chemistry.
[20] Eden R Martin,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[21] Hemani,et al. MRC IEU UK Biobank GWAS pipeline version 2 , 2019 .
[22] D. Lawson,et al. Apparent latent structure within the UK Biobank sample has implications for epidemiological analysis , 2019, Nature Communications.
[23] O. Andreassen,et al. Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer’s disease , 2018, Acta Neuropathologica.
[24] M. Weiner,et al. Serum triglycerides in Alzheimer’s disease: Relation to neuroimaging and CSF biomarkers , 2018, bioRxiv.
[25] Jason Weller,et al. Current understanding of Alzheimer’s disease diagnosis and treatment , 2018, F1000Research.
[26] G. Davey Smith,et al. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians , 2018, British Medical Journal.
[27] Valeriia Haberland,et al. The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.
[28] S. Burgess,et al. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates , 2018, European Journal of Epidemiology.
[29] L. Ferrucci,et al. Evidence for brain glucose dysregulation in Alzheimer's disease , 2018, Alzheimer's & Dementia.
[30] C. Rowe,et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.
[31] A. Saykin,et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study , 2018, PLoS medicine.
[32] A. Sayago,et al. Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[33] Hugh S. Markus,et al. Branched-chain amino acids and Alzheimer’s disease: a Mendelian randomization analysis , 2017, Scientific Reports.
[34] Michael W. Weiner,et al. Metabolic network failures in Alzheimer's disease: A biochemical road map , 2017, Alzheimer's & Dementia.
[35] L. Farde,et al. Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study , 2017, Journal of Alzheimer's disease reports.
[36] R. Xiao,et al. ApoE rs429358 and rs7412 Polymorphism and Gender Differences of Serum Lipid Profile and Cognition in Aging Chinese Population , 2017, Front. Aging Neurosci..
[37] Cathie Sudlow,et al. UK Biobank: opportunities for cardiovascular research , 2017, European heart journal.
[38] Debbie A Lawlor,et al. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies , 2017, American journal of epidemiology.
[39] G. Corso,et al. Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia , 2017, Dementia and Geriatric Cognitive Disorders Extra.
[40] Y. An,et al. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study , 2017, PLoS medicine.
[41] Stephen Burgess,et al. Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants , 2016, Epidemiology.
[42] Inês Barroso,et al. Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis , 2016, PLoS medicine.
[43] V. Gudnason,et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals , 2016, Alzheimer's & Dementia.
[44] K. Blennow,et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.
[45] G. Davey Smith,et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.
[46] C. Itsiopoulos,et al. Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer's Disease , 2015, BioMed research international.
[47] P. Calder,et al. Functional Roles of Fatty Acids and Their Effects on Human Health. , 2015, JPEN. Journal of parenteral and enteral nutrition.
[48] Michael T. Heneka,et al. Innate immune activation in neurodegenerative disease , 2014, Nature Reviews Immunology.
[49] Derick R. Peterson,et al. Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.
[50] C. DeCarli,et al. Associations between serum cholesterol levels and cerebral amyloidosis. , 2014, JAMA neurology.
[51] Huaxi Xu,et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.
[52] D. Lawlor,et al. Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort , 2012, International journal of epidemiology.
[53] D. Lawlor,et al. Cohort Profile: The ‘Children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children , 2012, International journal of epidemiology.
[54] P. Calder. Fatty acids and inflammation: the cutting edge between food and pharma. , 2011, European journal of pharmacology.
[55] H. Arrighi,et al. Apolipoprotein E ε4 Prevalence in Alzheimer’s Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-Analysis , 2010, Dementia and Geriatric Cognitive Disorders.
[56] Constantine G. Lyketsos,et al. Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets? , 2010, NeuroMolecular Medicine.
[57] L. Ferrucci,et al. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.
[58] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[59] Tom R. Gaunt,et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. , 2009, American journal of human genetics.
[60] M. Hayden,et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer’s disease mouse models with abundant Aβ in plasma , 2006, Neurobiology of Disease.
[61] G. Alexander,et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[62] P. O'Brien,et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.
[63] H. Sørensen,et al. Research in Health Care , 1996 .
[64] W. M. van der Flier,et al. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. , 2017, Journal of Alzheimer's disease : JAD.
[65] S. Snowden,et al. Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer's Disease Pathogenesis. , 2015, Journal of Alzheimer's disease : JAD.
[66] Y. Hannun,et al. An overview of sphingolipid metabolism: from synthesis to breakdown. , 2010, Advances in experimental medicine and biology.